Analysts take a look at Esperion Therapeutics Inc (NASDAQ:ESPR) having this to say.

November 15, 2017 - By Stephen Andrade

 Analysts take a look at Esperion Therapeutics Inc (NASDAQ:ESPR) having this to say.
Investors sentiment decreased to 1.22 in Q2 2017. Its down 0.52, from 1.74 in 2017Q1. It is negative, as 12 investors sold Esperion Therapeutics Inc shares while 37 reduced holdings. 26 funds opened positions while 34 raised stakes. 19.33 million shares or 18.76% more from 16.28 million shares in 2017Q1 were reported.
Barclays Public Llc has 0% invested in Esperion Therapeutics Inc (NASDAQ:ESPR). Vanguard Inc has invested 0% in Esperion Therapeutics Inc (NASDAQ:ESPR). Tower Rech Capital Limited Co (Trc) has invested 0.03% in Esperion Therapeutics Inc (NASDAQ:ESPR). Pub Employees Retirement Of Ohio reported 29,555 shares. Equitec Proprietary Limited Liability holds 418 shares. Hall Laurie J Trustee holds 0% or 280 shares in its portfolio. Art Advsrs Ltd Liability reported 55,460 shares stake. Two Sigma Limited Liability Com holds 0.06% or 6,857 shares. Pictet Asset holds 0.03% or 272,881 shares. Proshare Advsr Lc, a Maryland-based fund reported 12,912 shares. Deutsche Fincl Bank Ag accumulated 167,872 shares. Aqr Ltd Llc reported 0% stake. Bnp Paribas Arbitrage owns 1,586 shares or 0% of their US portfolio. Invesco reported 292,917 shares. Minnesota-based Ameriprise Fin Inc has invested 0% in Esperion Therapeutics Inc (NASDAQ:ESPR).

Esperion Therapeutics Inc (NASDAQ:ESPR) Ratings Coverage

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Esperion Therapeutics had 46 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Buy” rating by Cowen & Co on Thursday, September 7. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) earned “Buy” rating by Northland Capital on Tuesday, October 3. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Buy” rating given on Thursday, June 30 by Needham. The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) has “Sell” rating given on Tuesday, September 29 by Chardan Capital Markets. The stock has “Sell” rating by Chardan Capital Markets on Friday, August 7. The company was downgraded on Monday, November 14 by Citigroup. RBC Capital Markets maintained the shares of ESPR in report on Thursday, February 23 with “Sector Perform” rating. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The rating was maintained by Cowen & Co with “Buy” on Wednesday, October 18. The firm has “Buy” rating by Stifel Nicolaus given on Monday, June 26. Below is a list of Esperion Therapeutics Inc (NASDAQ:ESPR) latest ratings and price target changes.

18/10/2017 Broker: Needham Rating: Buy New Target: $72.0 Maintain
18/10/2017 Broker: Cowen & Co Rating: Buy New Target: $64.0 Maintain
03/10/2017 Broker: Northland Capital Rating: Buy New Target: $72.0 Maintain
07/09/2017 Broker: Cowen & Co Rating: Buy New Target: $64.0 Initiate
11/08/2017 Broker: Bank of America Rating: Hold
09/08/2017 Broker: Deutsche Bank Rating: Buy Old Target: $48 New Target: $64 Maintain
09/08/2017 Broker: Jefferies Old Rating: Hold New Rating: Buy Old Target: $55 Upgrade
11/07/2017 Broker: Jefferies Rating: Hold New Target: $55 Initiates Coverage On
26/06/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $60.0000 Maintain
22/06/2017 Broker: Citigroup Rating: Buy

About 48,679 shares traded. Esperion Therapeutics Inc (NASDAQ:ESPR) has risen 133.75% since November 15, 2016 and is uptrending. It has outperformed by 117.05% the S&P500.

Esperion Therapeutics, Inc. is a lipid management company. The company has market cap of $1.20 billion. The Firm is a late-stage pharmaceutical firm focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . It currently has negative earnings. With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

More important recent Esperion Therapeutics Inc (NASDAQ:ESPR) news were published by: Globenewswire.com which released: “Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference” on November 09, 2017, also Globenewswire.com published article titled: “Esperion to Participate in Fireside Chat at the Jefferies 2017 London …”, Prnewswire.com published: “Biotech Stocks on Investors’ Radar — Curis, Egalet, Esperion Therapeutics …” on November 02, 2017. More interesting news about Esperion Therapeutics Inc (NASDAQ:ESPR) was released by: Streetinsider.com and their article: “Esperion Therapeutics (ESPR) Commences Pivotal Phase 3 Study for the Bempedoic …” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.